SURMOUNT-5

What is SURMOUNT-5?

The head-to-head everyone wanted: tirzepatide against semaglutide for weight management in non-diabetic adults with obesity (Aronne et al., NEJM 2025, PMID 40353578).

Tirzepatide reached −20.2% against semaglutide's −13.7% at 72 weeks, a 6.5-point gap. It is the strongest single argument for paying more for tirzepatide, and sellers of both cite it.

Related reading: SURMOUNT-5: The Head-to-Head, Run Properly

GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.

Where SURMOUNT-5 comes up on this site

On GLP Watchdog, SURMOUNT-5 comes up in 3 research articles and 1 tool.

Other terms under trial

• SURMOUNT-2
• SURMOUNT-3
• SURPASS-2
• SUSTAIN-6
• REWIND
• PIONEER 6
• STEP-HFpEF
• EXSCEL
• ELIXA
• AMPLITUDE-O
• HARMONY OUTCOMES
• SCALE Diabetes
• STEP 2
• SUMMIT
• SCALE Maintenance

Where the evidence lives

• The full GLP-1 glossary (150 terms, 8 categories)
• Research articles — written from primary sources
• Tools and calculators
• Compare GLP-1 telehealth providers